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Abstract: 
 
Previously published reports indicate that serum copper levels are elevated in prostate 
cancer (PCa) patients and that increased copper uptake can be used as a means to 
image prostate tumors. It is unclear, however, to what extent copper is required for PCa 
cell function as we observed only modest effects of chelation strategies on the growth of 
these cells in vitro. With the goal of exploiting PCa cell proclivity for copper uptake, we 
developed a “conditional lethal” screen to identify compounds whose cytotoxic actions 
were manifest in a copper-dependent manner. Emerging from this screen were a series 
of dithiocarbamates, which when complexed with copper, induced Reactive Oxygen 
Species (ROS)-dependent apoptosis of malignant, but not normal, prostate cells. One of 
the dithiocarbamates identified, Disulfiram (DSF), is an FDA approved drug that has 
previously yielded disappointing results in clinical trials in patients with recurrent prostate 
cancer. Similarly, in our studies DSF alone had a minimal effect on the growth of PCa 
tumors when propagated as xenografts. However, when DSF was coadministered with 
copper a very dramatic inhibition of tumor growth in models of hormone sensitive and of 
castrate resistant disease was observed. Furthermore, we determined that prostate 
cancer (PCa) cells express high levels of CTR1, the primary copper transporter, and 
additional chaperones that are required to maintain intracellular copper homeostasis. 
The expression levels of most of these proteins are increased further upon treatment of 
AR-positive PCa cell lines with androgens. Not surprisingly robust CTR1-dependent 
uptake of copper into PCa cells was observed; an activity that was accentuated by 
activation of androgen receptor (AR). Given these data linking AR to intracellular copper 
uptake, we believe that dithiocarbamate/copper complexes are likely to be effective for 
the treatment of PCa patients whose disease is resistant to classical androgen ablation 
therapies.  
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INTRODUCTION 
 
Patients with prostate cancer (PCa) typically undergo a regimen of endocrine treatments 
designed to block the transcriptional activity of the androgen receptor (AR) by either 
decreasing the production of endogenous androgens (e.g. GnRH agonists) or 
competitively inhibiting the activities of androgenic ligands (e.g. bicalutamide) [1]. 
Unfortunately, these therapies are not curative, and most patients experience relapse of 
their disease to a hormone-refractory or castration-resistant state. In castration-resistant 
prostate cancer (CRPC), the AR signaling axis remains intact, and, thus, most cancers 
are initially responsive to second line endocrine therapies such as CYP17 inhibitors 
(Abiraterone) and next-generation AR antagonists (Enzalutamide) [2-5]. The therapeutic 
lifespan of these drugs is relatively short, and there is a growing sentiment in the field 
that the resolution of the problem of resistance does not lie in the development of better 
AR antagonists/steroid synthesis inhibitors. This position is supported by a large amount 
of data indicating that the current approaches to achieve androgen ablation can interrupt 
regulatory feedback loops leading to (a) upregulation of steroidogenesis [6, 7], (b) 
increased receptor and coregulator expression [8, 9], (c) neuroendocrine differentiation 
of PCa cells [10, 11], and (d) the selection for gene translocations/RNA splicing events 
or receptor mutations that result in the production of constitutively active AR variants [12-
14]. These activities have been confirmed in human tumors and hence are likely to 
contribute in a significant manner to treatment failure [15]. Thus, although tremendous 
progress has been made of late in treating prostate cancer, there is clearly a need for 
agents that target this disease in a unique manner. 
 
 
Whereas most attention has focused on AR as a therapeutic target, it is clear that there 
are other useful targets, the pharmaceutical exploitation of which are likely to impact 
PCa progression. Notable in this regard are clinical studies that have highlighted the 
potential utility of targeting MET and SRC proto-oncogenes, AKT and several different 
growth factor receptors [16]. To complement this approach we mined the current 
literature on PCa and available gene expression data to identify pathways and 
processes whose activity was restricted or particularly active in PCa. In this manner we 
determined that all of the major components of the processes involved in uptake and 
trafficking of copper were upregulated in PCa. Interestingly, there is considerable data 
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indicating that both circulating and intratumoral copper levels are elevated in PCa 
patients [17-20]. It is not clear why PCa has such a proclivity for copper uptake although 
copper has been suggested to play a role in RAS/MAP kinase pathway activation, a 
pathway that has been shown to have a role in cancer pathogenesis [21]. Whereas 
copper is an essential trace element required for the activity of a large number of 
enzymes and structural proteins, the concentrations within PCa clearly exceed that 
required to support viability. Herein we describe our efforts to define the mechanisms by 
which PCa cells regulate copper homeostasis and how this can be exploited in the 
development of therapeutic agents that disrupt these activities.  
 
 
MATERIALS AND METHODS 
 
Chemicals: 
Methyltrienolone (R1881) was purchased from PerkinElmer (Waltham, MA) and 
dissolved in DMSO. TTM, DSF, PDTC, BCS, CuSO4, NAC and LGR were obtained from 
Sigma (St Louis, MO). TTM, DSF and PDTC were dissolved in DMSO while BCS, 
CuSO4, NAC and LGR in water. EUK118 was from Cayman Chemical (Ann Arbor, MI). 
Copper-64 was prepared at Washington University (St. Louis, MO).  
 
Cell culture:  
VCaP, LNCaP, 22RV1, PC3 and RWPE-1 parental cell lines were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA); which authenticates cell lines 
by short tandem repeat profiling and passaged for less than 6 months. VCaP cells were 
cultured in DMEM while LNCaP, 22RV1 and PC3 cells in RPMI 1640 (Life 
TechnologiesTM, Grand Island, NY). All medias were supplemented with 8% fetal bovine 
serum (Sigma), 1 mM sodium pyruvate and 0.1 mM non-essential amino acids (Life 
TechnologiesTM) and cells were maintained in a 37°C incubator with 5% CO2. For 
androgen treatment experiments, cells were plated in the same media lacking phenol 
red and supplemented with 8% charcoal-stripped fetal bovine serum. 
 
Proliferation assay: 
VCaP (10,000 cells/well) or LNCaP, 22RV1, PC3, RWPE-1 (5,000 cells/well) were 
seeded in 96-well plates containing regular FBS containing media. The following day, 
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the cells were treated as indicated for an additional 72 hr. Cell proliferation was 
measured using a fluorometric resazurin reduction method (Cell Titer-Blue, Promega, 
Madison, WI). Each sample was performed in triplicate, and the results from a 
representative experiment are shown. Results are expressed as relative fluorescence ± 
SE (n=3). 
 
Apoptosis assay: 
VCaP cells were collected and double stained with Alexa Fluor 488 Annexin V and Sytox 
(Invitrogen) according to the manufacturer’s instruction. Annexin V-positive cells were 
considered apoptotic, and their percentage of the total number of cells was calculated. 
Ten thousand events were collected for each sample using a BD Accuri C6 flow 
cytometer (BD San Jose, CA) and data were analyzed using the CFlow Plus program 
software (BD San Jose, CA). 
 
ROS generation assay: 
Treated cells were stained with the oxidation-sensitive dye H2DCFDA (5 µmol/L) for 60 
min at 37oC and the treatment was terminated by ice-cold PBS. ROS generation was 
determined by FACS and quantified as the geometric mean fluorescence of a 
representative experiment. The increase in fluorescence of treated versus untreated 
samples is shown. 
 
Xenograft study: 
Five-week-old NOD.SCID.gamma male mice were obtained from the Cancer Center 
Isolation Facility (Duke Cancer Institute, Durham, NC). All experiments were performed 
according to local animal experimental ethics committee guidelines, and were approved 
by an institutional review committee (IACUC). VCaP (2 × 106) Cells in 50% matrigel  (BD 
Matrigel Matrix, BD Biosciences, San Jose, CA) were injected subcutaneously into the 
mouse right flank. Tumor size was measured with calipers and tumor volume was 
calculated using the formula volume = (width2 × length)/ 2. When tumor size reached 
200 mm3, mice bearing tumors were randomized into 4 groups (n=12). Each group 
received two separate daily i.p. injections of the following treatments: (1) Control group 
(vehicle, vehicle) received 100 µl DMSO-Corn oil and 100 µl of physiological saline 
(0.9%). (2) The copper treated group received 100 µl (DMSO-Corn oil) and 100 µl of 
CuSO4 in physiological saline (0.5mg/kg). (3) The DSF treated group received 100 µl of 
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DSF (30mg/kg in DMSO-Corn oil) and 100 µl physiological saline. (4) The DSF/Copper 
group received 100 µl of DSF (30 mg/kg in DMSO-Corn oil) and 100 µl of CuSO4 
(0.5mg/kg) physiological saline. For 22RV1 xenograft study, 1 × 106 cells were injected 
subcutaneously into the mouse right flank. When tumor size reached approximately 150 
mm3, mice bearing tumors were randomized into 2 groups (n=5) to receive daily i.p. 
injections of the control (100 µl DMSO-Corn oil and 100 µl of physiological saline (0.9%) 
or DSF/Copper (100 µl of DSF (30 mg/kg in DMSO-Corn oil) and 100 µl of CuSO4 
(0.5mg/kg)). The study was terminated and mice were humanely euthanized when tumor 
volume reached ~1,000 mm3 (VCAP) or after 16 days of treatment (22RV1). Tumor 
growth up to day 16 was analyzed by two-way ANOVA followed by Bonferroni’s multiple 
comparison test. 
 
Gene expression analysis: 
Total RNA was isolated using the AurumTM Total RNA Mini-Kit according to the 
manufacturer’s instructions (Bio-Rad, Hercules, CA). Total RNA (1µg) was reverse-
transcribed to cDNA using iScriptTM cDNA synthesis Kit (Bio-Rad). The resulting cDNA 
was diluted 1:20 with water to use in qPCR analysis. qPCR was performed using the 
Bio-Rad SYBR green supermix with 0.2 µM of each forward and reverse primer and 2.5 
µl or 1.25 µl of diluted cDNA in a total reaction volume of 6.5 µl or 3.25 µl. PCR 
amplification was carried out using the Bio-Rad iQ4 or the CFX384 qPCR system. All 
primers used in the study were tested to have PCR efficiency between 100+/-10% and 
span intron/exon boundaries when possible. Fold induction was calculated using the 
2 −ΔΔCt method and GAPDH was used as the normalization control. Data shown are 
representative of at least three independent experiments. Gene-specific primers were 
purchased from Integrated DNA Technologies (Coralville, IA). 
 
Immunoblot analysis: 
Whole-cell extracts were prepared using RIPA buffer [50 mmol/L Tris-HCl (pH 7.5), 150 
mmol/L NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.05% SDS, 1 mmol/L 
EDTA, protease inhibitors (Sigma)]. Lysates were separated on SDS-PAGE (7% 
polyacrylamide gels), transferred onto nitrocellulose membranes, and detected using the 
following antibodies: CTR1 [22] or glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; Santa Cruz Biotechnology, Dallas, TX). 
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RNA silencing: (Small Interfering RNA Transfection): 
Synthetic small interfering RNA (siRNA) to knock down endogenous AR, CTR1, and 
nonspecific siRNA-control (siCTRL) were synthesized by Invitrogen, (Life 
TechnologiesTM, Grand Island, NY). VCaP cells were plated at equal densities in six-well 
plates (3.3x105 per well) overnight. Subsequently, cells were transfected with 50nmol/L 
siCTRL or siRNA against AR or CTR1 using DharmaFECT 1 transfection reagent 
following the manufacturer’s protocol (Dharmacon, Lafayette, CO). 48 hr. post-
transfection, the cells were treated overnight with 10nM R1881 and harvested for qPCR 
analysis or copper uptake studies.  
 
64Cu uptake assay: 
VCaP cells were treated with 64Cu (5µCi/ml as CuCl2) at 37oC in serum free medium and 
incubated for different time periods. After each incubation, cells were washed three 
times with cold PBS, treated with Cell Lysis Reagent (Promega) and the resulting cell 
lysates were transferred to separate micro-centrifuge tubes for gamma counting. The 
radioactivity in cell lysates as well as corresponding supernatants was determined using 
a gamma counter (Wallac Wizard 1480, Perkin-Elmer) and the values were normalized 
to the total protein content of cells for each well as determined by the Bradford assay. 
 
 
RESULTS 
 
Disruption of intracellular copper homeostasis as a means to inhibit prostate 
cancer cell growth. Previous studies have shown that human PCa xenografts 
propagated in mice have the ability to take up copper [23, 24]. However, the utility of 
manipulating copper uptake or intracellular copper biology has not been explored as a 
therapeutic modality in PCa. Thus, as a first step we undertook a study to evaluate the 
impact of copper chelation on PCa cell proliferation in vitro. As shown in Figure 1A, 
treatment with the copper chelator tetrathiomolybdate (TTM) efficiently inhibited the 
growth of AR-expressing LNCaP cells. Further, TTM also inhibited the growth of two 
different cellular models of CRPC: VCaP cells in which AR is overexpressed (Fig. 1B) 
and 22RV1 cells which express a constitutively active AR-splice variant (Fig. 1C). 
However, the effects of TTM in these cell lines were not as dramatic as that observed in 
LNCaP cells and could only be achieved when high concentrations of the chelator were 
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used. The most disappointing finding, however, was that TTM treatment also inhibited 
the growth of transformed normal epithelial RWPE-1 cells (Fig. 1D), suggesting that the 
therapeutic window for copper chelation therapy was extremely small. It was concluded 
therefore that copper chelation in and of itself was not likely to be a viable therapeutic 
option for PCa. 
 
The uptake and regulation of intracellular copper levels are tightly regulated reflecting 
the balance between the requirement for copper as a cofactor for many enzymes and 
structural proteins and the need to prevent the oxidative damage that is associated with 
the redox cycling of elemental copper within cells [25]. We reasoned, therefore, that it 
might be possible to employ a synthetic lethality approach to identify drugs whose 
cytostatic/cytocidal activity would capitalize on the ability of PCa cells to take up 
significant amounts of copper. Thus, we screened for small molecules that would inhibit 
the growth or induce apoptosis of VCaP cells and whose activity was attenuated by the 
co-administration of a sub-toxic dose of the copper chelator TTM. Using this approach 
we identified two chemically distinct drugs that are members of the dithiocarbamate 
family of metal binding compounds (Fig. 2A). One of the compounds identified, DSF 
(Disulfiram, tetraethylthiuram disulfide), has previously been identified in high-content 
screens for PCa therapeutics [26]. It is an orally administered drug that is approved for 
use in alcohol aversion therapy [27, 28]. The second drug identified, ammonium 
pyrrolidine dithiocarbamate (PDTC), is a known copper binding compound and has only 
been tested in vitro for anticancer activity [29]. Importantly, follow-up studies confirmed 
that when tested over a broad range of concentrations the growth inhibitory activity of 
these drugs in VCaP cells could be reversed by co-administration of a sub-toxic dose of 
the copper chelators TTM or Bathocuproine disulfonate (BCS) (Fig. 2B and C). Similarly, 
DSF dramatically inhibits the growth of 22RV1 cells and this activity can be reversed 
with BCS (Fig. 2D). This result is particularly significant as this cell line expresses a 
truncated constitutively active AR variant that renders the cells resistant to all of the 
currently available androgen synthesis inhibitors and antiandrogens (Fig. 2E) and is a 
well-validated model of advanced disease. DSF also has a profound copper-dependent 
effect on the growth of the AR-negative PC3 PCa cell line (Fig. 2F). Thus, the cytotoxic 
effect of DSF is not restricted to AR-positive prostate cancer cells. Finally, it was shown 
that DSF had no effect on the growth of normal RWPE-1 cells at the concentrations 
tested (Fig. 2G). We conclude from these studies that DSF and PDTC inhibit PCa cell 
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growth in a manner that likely capitalizes on the ability of these cells to accumulate 
copper. Defining the specific role for copper in dithiocarbamate activity was the goal of 
our next series of studies. 
 
The growth inhibitory activity of DSF is absolutely dependent on copper. 
Considering the copper binding specificity of the two chelators (TTM and BCS) utilized in 
our studies, it was likely that the growth inhibitory activity of DSF required its interaction 
with copper. We therefore asked whether copper supplementation could enhance the 
growth inhibitory activity of DSF. To this end, VCaP cells were treated with increasing 
concentrations of DSF alone or with copper supplementation. In this manner, we showed 
that copper supplementation enhances the cytotoxic effect of DSF (Fig. 3A). Thus, as 
opposed to DSF, the ability of TTM to inhibit prostate cancer cell proliferation was reversed by the 
co-administration of copper, highlighting the distinct mechanisms of action of the two drugs (Fig. 
3B). The ability of copper to enhance DSF cytotoxicity was confirmed in the AR-positive 
PCa cell lines LNCaP and 22RV1, as well as in the AR-negative PC3 cells (Fig. 3C-E). 
As expected, the treatment with the copper chelator BCS abrogated the cytotoxic effect 
of DSF in the presence of additional copper in all cells. Together, these results suggest 
that although the available copper in the media used in these studies is sufficient for 
DSF action, the efficacy of the drug can be enhanced significantly by additional copper 
supplementation. 
 
Reduction of copper from Cu(II) to Cu(I) by the metalloreductases is an obligate step for 
efficient transport across the plasma membrane by the high-affinity transporter CTR1 
[30, 31]. Indeed it has been shown previously that divalent metal ions do not inhibit 
copper uptake by CTR1, whereas an excess of silver ions that are isoelectronic and of 
similar size to Cu(I) block the CTR1-mediated copper uptake [32]. We therefore 
assessed the ability of Ag(I) to block DSF-mediated inhibition of cell growth. To this end, 
VCaP cells were treated with increasing concentrations of DSF alone or in the presence 
of additional copper to enhance the anti-proliferative effect of DSF. Interestingly, co-
administration of excess silver ions abolishes the cytotoxicity induced by both DSF alone 
or DSF in the presence of copper (Fig. 3F). This result is consistent with a role for 
CTR1-mediated uptake of copper in regulating the cytotoxic actions of DSF. In previous 
studies using cellular models of melanoma it has been shown that DSF:Au and DSF:Ag 
complexes are growth inhibitory [33]. However, the ability to reverse DSF:Cu activity with 
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Ag suggests that the DSF:Cu complex is functioning in a different manner in PCa cells. 
These data also suggest that tumors with high intrinsic copper levels, or those which can 
be manipulated to uptake copper, are likely to exhibit the greatest therapeutic response 
to DSF. 
 
DSF induces prostate cancer cell apoptosis. The impact of DSF and DSF:Cu on PCa 
cell apoptosis was evaluated by measuring Annexin V staining using flow cytometry. As 
shown in Figure 4, (and supplemental Fig. S1) treatment of VCaP cells for 24 hr. with 
DSF alone increased the Annexin V-positive cell population (5.1% of Annexin V+/Sytox-, 
and 2.7% of Annexin V+/Sytox+) as compared with control-treated cells (1.3% of Annexin 
V+/Sytox-, and 1.3% of Annexin V+/Sytox+). Even more pronounced effects of DSF on 
VCaP cells were observed at later time points (supplemental Fig. S2 (72hr. time point)). 
As expected the pro-apoptotic activity of DSF was dramatically enhanced in the 
presence of copper (DSF alone: 5.1% of Annexin V+/Sytox-, and 2.7% of Annexin 
V+/Sytox+, DSF + Cu: 38.8% of Annexin V+/Sytox-, and 22.3% of Annexin V+/Sytox+, 
(Fig. 4)). Addition of copper alone was without effect. In all cases DSF-dependent 
apoptosis was abrogated by the copper chelator BCS (Fig. 4). Together, these results 
indicate that DSF-mediated inhibition of prostate cancer cell growth can be attributed in 
large part to its ability to induce apoptosis in a copper-dependent manner.  
 
ROS as a mediator of the copper-dependent cytotoxic effects of DSF. Copper, a 
transition metal with multiple oxidation states, can participate in single electron transfer 
reactions. Therefore, given the chemistry of the interaction between copper and DSF, we 
hypothesized that the inherent redox shuttling of copper [Cu(I)/Cu(II)/Cu(III)] within Cu-
dithiocarbamate complexes could generate free radicals that would facilitate ROS 
formation [34-36]. It was of significance, therefore, that treatment of cells with the free-
radical scavenger N-acetyl-L-cysteine (NAC) blocked cell death induced by DSF:Cu, 
Similar results were obtained when PCa cells were treated with the free-radical 
scavenger, L-Glutathione reduced (LGR) in the presence of DSF alone or in combination 
with supplementary copper (Fig. 4). These antioxidants also blocked the cytotoxic 
actions of DSF:Cu in other PCa cells (Fig. S2 and data not shown).  
 
Both of the antioxidants NAC and LGR reversed the anti-proliferative effect of DSF in the 
presence or absence of added copper (Fig. 5A). Further, co-treatment of the VCaP cells 
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with EUK118, a synthetic catalytic scavenger of ROS with superoxide dismutase and 
catalase mimetic activity [37] blocked DSF-mediated inhibition of cell growth (Fig. 5B). 
Together, these results implicate ROS in DSF-mediated cell death. Thus, we directly 
measured intracellular free radical production in DSF-treated cells using the cell 
permeable oxidation sensitive dye CM-H2DCFDA. For this assay, VCaP cells treated for 
2 days with H2O2 were used as positive controls. Using this approach, we were able to 
establish that addition of DSF resulted in robust CM-H2DCFDA oxidation when 
compared with control-treated cells (Fig. 5C). To analyze whether elevation of 
intracellular copper is a prerequisite for the induction of oxidative stress, VCaP cells 
were co-incubated with the copper chelator BCS. As seen in Figure 5C, co-treatment 
with the copper chelator BCS blocked both DSF-dependent generation of ROS and 
apoptosis. These data are consistent with the idea that DSF:Cu induces PCa cell 
apoptosis secondary to its ability to induce intracellular ROS production.  
 
Copper enhances the growth inhibitory activity of DSF in xenograft models of 
prostate cancer. In agreement with our in vitro data, it has been demonstrated, using 
positron emission tomography (PET) imaging, that human PCa xenografts propagated 
as tumors in mice have a high capacity to uptake and accumulate copper [23, 24]. We 
therefore asked whether the therapeutic activity of DSF could be enhanced using copper 
supplementation to increase intratumoral copper within VCaP cells propagated as 
xenografts in immunodeficient mice. To this end, the effect of DSF alone or in 
combination with copper treatment was evaluated. For comparative purposes, a vehicle 
control group and a copper alone group were also included in this study. In this manner, 
it was shown that while DSF alone had only marginal effects on tumor growth, treatment 
with a combination of DSF and copper significantly decreased tumor growth (Fig. 6A). 
Subsequently, the effect of DSF and copper in a well-validated model of CRPC was 
evaluated. To this end, 22RV1 cells, which express a constitutively active AR-splice 
variant, were propagated as xenografts in castrated, immunodeficient mice. Similar to 
what we observed in VCaP cells, DSF:Cu efficiently inhibited the growth of 22RV1 
tumors when compared to vehicle treated mice (Fig. 6B). Taken together, the in vivo 
data are consistent with the in vitro data and reinforce the concept that the combined 
treatment of DSF and copper has superior activity in targeting PCa cells than either 
agent alone with no observable increase in animal toxicity or weight loss.  
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AR upregulates the expression of key proteins required for cellular copper 
homeostasis. Whereas the antiproliferative activities of DSF observed were not 
restricted to AR-positive PCa cells, we were intrigued by the observation that the 
expression of several proteins involved in the uptake and trafficking of copper were 
upregulated by androgens in VCaP cells. Specifically, using qPCR we determined that 
the synthetic androgen R1881 increased the transcript levels of CTR1 (copper uptake) 
ATP7B (copper trafficking) and STEAP4 (metallo/copper reductase) (Fig. 7A). 
Furthermore, small interfering RNAs (siRNAs) targeting AR dramatically reduced the 
androgen-mediated up-regulation of these transcripts (Fig. 7B), Importantly, androgens 
also increased CTR1 protein levels, an effect that was also dependent on AR (Fig. 7C). 
Additionally, at a concentration that inhibits the expression of secondary androgen 
responsive target genes (ex. INSIG1), cycloheximide treatment did not block the R1881-
mediated increase in CTR1, ATP7B or STEAP4 mRNA levels (supplemental Fig. S4). In 
LNCaP cells, only STEAP4 was shown to be upregulated by androgens (supplemental 
Fig. S5). This may relate to the differences in AR expression in the two models with 
VCaP cells exhibiting AR overexpression, and thus a good model of late stage CRPC, 
and LNCaP expressing less AR, modeling an earlier stage in the disease. This finding is 
significant as AR expression has been found to be consistently upregulated during tumor 
progression, and that a 2- to 3-fold increase in AR protein levels is sufficient to facilitate 
the transition of prostate cancer cells from a hormone-sensitive to a hormone-refractory 
state in experimental animal models [8]. Thus, we engineered LNCaP cells to express 
higher levels of AR and found that this resulted in significantly higher levels of CTR1 and 
ATP7B expression in response to androgen treatment (supplemental Fig. S5). 
Interestingly, similar results were obtained when the immortalized RWPE-1 prostate 
epithelial cell line was engineered to express high levels of AR (supplemental Fig. S5). 
Collectively, these findings validate CTR1, ATP7B and STEAP4 as bona fide AR target 
genes in prostate cancer cells. However, the insensitivity of RWPE-1-AR cells to DSF 
indicates that while androgens can increase the expression of proteins involved in 
copper homeostasis, this activity alone is not sufficient to confer sensitivity to these 
agents. Although it does suggest that in cells that have an inherent sensitivity to DSF, 
that upregulation of AR-target gene expression as occurs in late stage disease may 
sensitize cells to DSF:Cu. 
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Androgens increase cellular copper uptake. CTR1 is the primary copper transporter 
in mammalian cells and we have shown that it is significantly expressed in PCa cells and 
that androgens can further increase its expression. Given this observation, we sought to 
determine the importance of CTR1 on cellular copper uptake in PCa cells using 
radioactive copper (64Cu). As expected, siRNA-mediated CTR1 knockdown resulted in a 
significant decrease in 64Cu uptake (Fig. 7E) indicating that copper uptake into PCa cells 
is largely dependent on CTR1 expression. Next, we investigated the effect of androgen 
treatment on cellular copper uptake. As expected, there is a significant time-dependent 
increase in 64Cu uptake into PCa cells in the basal state and this uptake is accentuated 
when cells are pretreated with an androgen agonist (Fig. 7G). The uptake of 64Cu was 
quantitatively inhibited by co-incubation with a 100-fold molar excess of nonradioactive 
copper, a result that supports the involvement of a specific, saturable transporter in 
regulating copper uptake (Fig. 7G). We have also found that addition of DSF to the 
incubation media further increases the copper accumulation in cells (supplemental Fig. 
S6). However, it is unclear whether this is a consequence of DSF trapping copper within 
cells or if it is related to the reported metal ionophore activity of this compound [38, 39]. 
Regardless, these results suggest that the increased accumulation of copper in PCa 
cells can be attributed to a significant expression of CTR1, and that the expression and 
functional activity of this transporter can be upregulated by androgens. The latter finding 
is of particular significance, as it suggests CRPC cells take up a significantly higher level 
of copper and would by inference exhibit increased sensitivity to DSF.  
 
 
DISCUSSION: 
 
A common objective in the development of chemotherapeutics is to identify compounds 
whose cytostatic/cytotoxic actions require, or are reinforced by, proteins or processes 
that are selectively expressed in malignant cells. It was of considerable importance 
therefore, that several investigators noted that PCa has a particular proclivity for copper 
uptake that was not apparent in normal prostate [17-19]. These findings, together with 
the observation that copper was required for angiogenesis in PCa, led to the initiation of 
several clinical trials that evaluated the impact of copper chelation in patients with 
CRPC. Unfortunately, no significant impact on clinical outcomes in PCa was observed 
using this therapeutic strategy [40, 41]. Copper chelation using TTM is currently being 
evaluated in several clinical trials, alone or in combination with chemotherapy/radiation, 
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in patients with advanced solid tumors, including breast, lung, esophageal, colorectal, 
and hepatocellular carcinoma (www.clinicaltrials.gov). It will be of interest to see whether 
this strategy works in other cancers and if information can be drawn from these studies 
that would inform better approaches to use chelation therapy in PCa. However, 
considering the narrow therapeutic window we observed in the sensitivity of normal vs. 
malignant prostate cancer cells to copper chelators in vitro, it is unlikely that copper 
chelation, as currently contemplated, will play a significant role in the management of 
PCa. 
 
Recently, we made the unexpected finding that both AR-positive and AR-negative PCa 
cells overexpress many of the proteins required for copper uptake and trafficking and 
that in AR-positive PCa cells, the expression of these proteins can be accentuated by 
androgens. Further, a robust uptake of copper into PCa cells was observed; an activity 
that was increased further by androgens. With a view to exploiting this propensity for 
copper uptake we developed a “conditional lethal” screen to identify compounds whose 
cytotoxic activities required copper. Using this approach two drugs, both members of the 
dithiocarbamate family of metal binding compounds, were identified. The actions of both 
of these drugs were inhibited by classical copper chelators; a finding that highlights their 
unique mechanism of action. One of the compounds identified, DSF, an FDA approved 
drug, has extensive clinical and pharmacologic experience and is used for the treatment 
of alcohol abuse [27, 28, 42, 43]. Interestingly, this drug was identified previously in a 
screen for PCa therapeutics and was subsequently evaluated in a multicenter phase II 
clinical study in men with non-metastatic recurrent prostate cancer after local therapy. 
The results of this trial were disappointing and no significant benefit of the drug was 
observed [44]. However, in studies performed both in vitro and in vivo we have found 
that the activity of DSF absolutely requires copper. Using Positron PET imaging and 
64Cu as an imaging agent it was observed by others that PCa tumors propagated as 
xenografts have a particularly high capacity to accumulate copper [23, 24]. However, 
notwithstanding this ability to accumulate copper, we demonstrated that DSF has a 
minimal impact on tumor growth unless animals were supplemented with copper. Thus, 
although PCa cells express the transporters that enable them to uptake copper, it 
appears as if the available copper in the blood of unsupplemented animals, and by 
inference humans, is not sufficient to confer sensitivity to DSF. This has important 
implications with respect to the interpretation of the recently completed clinical trials of 
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DSF as it brings into question whether or not the treated tumors had copper levels 
sufficient to confer sensitivity to the drug. To address this issue we have designed, and 
will soon enroll into, a clinical trial (FDA approval IND 116012) to examine the antitumor 
activity of DSF in the setting of parenteral copper supplementation. The primary goal of 
this trial is to evaluate the feasibility of manipulating intratumoral copper levels in 
patients with PCa as a means to sensitize the tumors to DSF.  
 
In preclinical studies, several mechanisms of action underlying the anti-proliferative 
effect of DSF has been reported including generation of ROS, inhibition of DNA 
methyltransferase and ubiquitin-proteasome pathway, activities that are potentiated by 
copper supplementation [45-50]. However, these actions were only observed using drug 
concentrations far exceeding that which we demonstrated to effectively inhibit PCa cell 
growth. In our studies, it was demonstrated that intracellular ROS production is 
dramatically elevated in cells upon co-treatment with DSF and copper. This activity is 
likely to be important for therapeutic efficacy as PCa cell apoptosis induced by DSF:Cu 
can be inhibited by blocking ROS production using free radial scavengers. Although the 
mechanisms underlying ROS production were not addressed in our study, it is likely due 
to the free radical formation that results from the inherent redox shuttling of copper 
(Cu(I)/Cu(II)) within Cu-dithiocarbamate complexes [34, 35, 38]. These highly reactive 
species target a variety of biological molecules including DNA, RNA, cholesterol, lipids, 
carbohydrates, and proteins. In normal cells, free radical generation is balanced by 
processes that facilitate antioxidant defense. However, this equilibrium is upset in 
prostate cancer cells, favoring oxidation and increased ROS production. A question that 
remains unanswered is why the DSF:Cu complex is selectively toxic to malignant vs. 
non-malignant PCa cells. The ability of PCa to accumulate copper is certainly important; 
however, it is also likely that the highly oxidative environment within cancer cells 
predisposes them to ROS generation [51-55]. Understanding the mechanism(s) 
underlying this specificity will likely inform the optimal use of this drug or a related 
drug:metal conjugate.  
 
The mechanism(s) by which copper is taken up into cells has been elucidated in detail. 
In blood, copper (Cu(II)) is highly protein bound being associated with ceruloplasmin or 
albumin. At the cell surface metalloreductases (STEAP family members) convert Cu(II) 
to Cu(I) allowing it to be transported into cells by the CTR1 [16]. Once inside the cell, 
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carrier cytoplasmic metallochaperones deliver copper to specific cellular targets and 
compartments. One of the surprising findings of our study is that the expression of all of 
the key regulators of copper homeostasis (CTR1, STEAP4, ATP7B and ATP7A) are 
either expressed at a high basal level and/or can be induced upon AR activation. Not 
surprisingly, we have shown that copper uptake into PCa cells can be increased by 
androgens although it is important to note that the basal expression of these proteins 
enables the uptake of enough copper to sensitize cells to DSF. Interestingly, we have 
shown that DSF treatment increases overall copper accumulation into PCa cells. 
However, it is unclear whether this reflects an ability of DSF to trap copper within cells or 
if DSF can facilitate copper uptake by functioning as an ionophore [38, 39].  
 
In summary, we have demonstrated that PCa cells accumulate copper and that this can 
be exploited to sensitize cells to the cytotoxic actions of dithiocarbamates. The absolute 
requirement of copper supplementation for the positive therapeutic action of DSF in 
animals has informed a clinical trial which will explore the impact of copper 
supplementation on DSF efficacy in PCa patients with advanced disease.  
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FIGURE LEGENDS 
 
Figure 1. Effect of copper chelation on the growth of prostate cancer cells. LNCaP 
(A), VCaP (B), and 22RV1 (C) malignant prostate cells as well as the normal epithelial 
RWPE-1 cell line (D) were treated for 72 hr. with increasing concentrations of TTM. Cell 
viability was measured using a fluorometric resazurin reduction method and results are 
expressed as relative fluorescence ± SE (n=3). Representative experiments are shown.  
 
Figure 2. Identification of compounds that rely on copper to inhibit the growth of 
prostate cancer cells. (A) Chemical structure of the compounds identified. VCaP cells 
were treated for 72 hr. with increasing concentrations of DSF alone or in combination 
with sub toxic doses of the copper chelators TTM or BCS (B) or with PDTC alone or in 
combination BCS (C). D, 22RV1 cells were treated for 72 hr. with increasing 
concentrations of DSF alone or in combination with BCS. E, 22RV1 cells were treated 
for 72 hr. with increasing concentrations of MDV3100 alone or in combination with 
R1881. The AR negative PC3 (F) or the normal immortalized prostate RWPE-1 (G) cell 
lines were treated for 72 hr. with increasing concentrations of DSF alone or in the 
presence of the copper chelator BCS. The results from representative experiments are 
shown and are expressed as relative fluorescence ± SE (n=3). 
 
Figure 3. Copper supplementation enhances the cytotoxic effect of DSF. A, VCaP 
cells were treated for 72 hr. with increasing concentrations of DSF alone or in the 
presence of 0.1 µM CuSO4. Copper supplementation enhances the cytocidal effect of 
DSF and treatment with the copper chelator BCS reversed the anti-proliferative effect of 
DSF alone or when in the presence of copper. B, LNCaP cells were treated for 72 hr. 
with increasing concentrations of the copper chelator TTM. Copper supplementation 
reverses the anti-proliferative effect of TTM. LNCaP cells (C), 22RV1 (D), and PC3 (E) 
prostate cancer cells were treated for 72 hr. with increasing concentration of DSF. Co-
treatment with 0.1 µM of CuSO4 enhances the cytocidal effect of DSF. F, VCaP cells 
were treated with increasing concentration of DSF alone or in the presence of copper. 
Co-treatment with excess of Ag+NO3+ reverses the cytotoxic effects of DSF. 
 
Figure 4. Disulfiram (DSF) induces prostate cancer cell apoptosis. VCaP cells were 
incubated with vehicle, DSF, copper alone or DSF in combination with copper. The 
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effects of the copper chelation (BCS) as well as the antioxidants (NAC and LGR) were 
evaluated. Following 24 hr. drug treatments cells were harvested, stained with Annexin 
V-Alexa Fluor® 488 and Sytox red dead cells staining, and analyzed by flow cytometry. 
The populations of Annexin V-/Sytox-, Annexin V+/Sytox-, and Annexin V+/Sytox+ 
correspond to live cells, early apoptotic cells, and late apoptotic cells respectively. 
Representative plots of one set of triplicate experiments are presented. 
 
Figure 5. Antioxidants reverse the inhibitory effect of DSF on prostate cancer cell 
growth. VCaP cells were treated for 72 hr. with increasing concentrations of DSF alone 
or in combinations with 0.1 µM of CuSO4. A, Co-treatment with the antioxidants NAC or 
LGR reverse the inhibitory growth activity exerted by DSF on VCaP cells. B, EUK118, a 
synthetic catalytic scavenger of ROS with superoxide dismutase and catalase mimetic 
activity blocked DSF mediated inhibition of cell growth. C, Disulfiram induces ROS 
production. VCaP cells were incubated for 48 hr. with vehicle or DSF either alone or in 
combination with copper. The effect of the copper chelator BCS was also evaluated. As 
a positive control VCaP cells were treated with 500 µM H2O2. Cells were then incubated 
with 5 µM of CM-H2DCFDA for 60 min at 37oC, washed twice with PBS and the intensity 
of fluorescence was measured using flow cytometry. A representative result from one of 
three experiments is shown. 
 
Figure 6. Copper enhances the inhibitory effect of Disulfiram on tumor growth. A. 
Tumor growth rate of a subcutaneous VCaP xenograft in male NOD SCID gamma mice 
is represented. Tumor size was allowed to proceed until they reached 0.2 cm3, at which 
time mice were randomized into 4 groups (n=12) and treated with either vehicle, copper, 
DSF alone or DSF in combination with copper. B. Mice bearing 22RV1 xenograft tumors 
were grown until ~ 0.15 cm3 tumor volume, at which time mice were randomized into two 
group (n=5) to receive daily treatment with either vehicle or DSF in combination with 
copper. Data points are mean of tumor volume in each experimental group; error bars 
are SE. Statistical significance from Veh, Veh is denoted by stars (*), (p<0.05). 
 
Figure 7. Androgen up-regulates the expression of genes required for copper 
uptake and the maintenance of intracellular copper homeostasis. A. VCaP cells 
were treated for 12 hr. with either vehicle or increasing concentrations of R1881, and the 
mRNA expression of CTR1, ATP7B or STEAP4 were evaluated using qPCR. Results 
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are expressed as fold induction over vehicle-treated cells ±SE (n=3). The data shown 
are representative of three independent experiments. B. VCaP cells were transiently 
transfected with a Stealth siRNA-control targeting a negative control (siCTRL) or AR 
(siAR). Two days later, cells were treated overnight with either vehicle (white bars) or 10 
nM R1881 (black bars). The mRNA expression of CTR1, ATP7B or STEAP4 was 
assessed using qPCR. C. VCaP cells were transfected as described in B with mock, 
siCTRL or siAR and treated for 24 hr. Whole-cell extracts were subjected to Western 
immunoblot analysis using antibodies direct against CTR1 or GAPDH (loading control). 
D. VCaP cells were transiently transfected with a nonspecific siRNA-control (siCTRL) or 
a siRNA targeting CTR1 (siCTR1-B; siCTR1-C). qPCR analysis confirming siRNA CTR1 
knockdown at 72 hr. post-transfection is represented. E. VCaP cells, transiently 
transfected with a nonspecific siRNA-control (siCTRL) or a siRNA targeting CTR1 
(siCTR1-B; siCTR1-C), were incubated with 5µCi/ml 64CuCl2 for 2 hr. 64Cu accumulation 
was measured using a γ-counter and normalized to the protein concentration of the cell 
lysates. F. VCaP Cells were treated for 24 hr. with either vehicle or 10 nM R1881 and 
incubated with 5µCi/ml 64CuCl2 for 30-240 min at 37oC. 64Cu uptake was quantified and 
normalized to protein concentrations of cells lysates. G. 100-fold molar excess of 
nonradioactive copper (CuSO4) was added to the media with 5µCi/ml 64CuCl2 and 
incubated for 2 hr. 64Cu uptake was measured and compared with control cells 
incubated in the absence of cold copper and presented as mean ±SE, n=3. 
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SUPPLEMENTARY FIGURE LEGENDS: 
 
Supplemental figure S1. Disulfiram induces prostate cancer cell apoptosis. VCaP 
cells were incubated with vehicle, DSF, copper alone or DSF in combination with copper. 
The effects of the copper chelation (BCS) as well as the antioxidants (NAC and LGR) 
were evaluated. Following 24 hr. drug treatments cells were harvested, stained with 
Annexin V-Alexa Fluor® 488 and Sytox red dead cells staining, and analyzed by flow 
cytometry. Percentage of cell population stained with Annexin V and/or Sytox under 
different treatments is represented. 
 
Supplemental figure S2. The effect of Disulfiram on prostate cancer cell apoptosis 
is more pronounced at 72hr. VCaP cells were incubated with either vehicle or DSF for 
72 hr. The effect of the copper chelation (BCS) was also evaluated. Cells were then 
harvested, stained with Annexin V-Alexa Fluor® 488 and Sytox red dead cells staining, 
and analyzed by flow cytometry. The populations of Annexin V-/Sytox-, Annexin V+/Sytox-
, and Annexin V+/Sytox+ correspond to live cells, early apoptotic cells, and late apoptotic 
cells respectively. Representative plots of one set of triplicate experiments are 
presented. 
 
Supplemental figure S3. Disulfiram induces 22RV1 prostate cancer cell apoptosis. 
22RV1 cells were incubated with vehicle, DSF, copper alone or DSF in combination with 
copper. The effects of the copper chelation (BCS) as well as the antioxidants (NAC and 
LGR) were evaluated. 24 hr. later, cells were harvested, stained with Annexin V-Alexa 
Fluor® 488 and Sytox red dead cells staining, and analyzed by flow cytometry. The 
populations of Annexin V-/Sytox-, Annexin V+/Sytox-, and Annexin V+/Sytox+ correspond 
to live cells, early apoptotic cells, and late apoptotic cells respectively. Representative 
plots of one set of triplicate experiments are presented. 
 
Supplemental figure S4. VCaP cells were pretreated for 1 hr. with either vehicle or 0.1 
µg/ml cycloheximide followed by vehicle (Veh) or 10 nM R1881 for 12 hr. and the mRNA 
expression of CTR1, ATP7B, STEAP4 or INSIG1 were evaluated using qPCR. Results 
as fold induction over vehicle-treated cells ±SE (n=3). 
 
 2 
Supplemental figure S5. RWPE-1 Empty Vector control (RWPE-1 EV) or RWPE-1 
overexpressing AR (RWPE-1 AR) cells were treated overnight with either vehicle or 
increasing concentration of R1881 and the mRNA expressions of CTR1 (A) and ATP7B 
(B) using qPCR were evaluated. RWPE-1 EV and AR cells (C) or LNCaP cells (D) were 
treated overnight with either vehicle or 10 nM R1881 and their whole-cell extracts were 
subjected to Western blot analysis. Blots were probed for AR, CTR1 or GAPDH, loading 
control. E. LNCaP control (LNCaP EV) or LNCaP overexpressing AR (LNCaP AR) cells 
were treated overnight with either vehicle or increasing concentration of R1881 and the 
mRNA expressions of ATP7B using qPCR was evaluated. !
Supplemental figure S6. VCaP Cells were incubated with 5µCi/ml 64CuCl2 for 30-120 
min at 37oC in the presence of either vehicle or 1µM DSF. 64Cu uptake was quantified 
and normalized to protein concentrations of cells lysates. 
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